Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir vs Lopinavir/Ritonavir with Truvada in ART-Naive HIV
NCT00632970Phase 4Terminated
- Sponsor
- George Washington University
- Start
- Feb 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by George Washington University. Primary endpoint: Absolute Change in CD4 Cell Counts at 48 weeks. Started Feb 2008; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00632970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00632970.